Evidence of Improved Survival When Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management Abstract #878

Introduction: ENETs and UKINETs Guidelines emphasize that patients with NETs should be referred to NET specialist clinics (NSC) and these clinics should use a multidisciplinary team (MDT) for decision making. In Belfast there has been an NSC for several decades and an MDT since 2000.
Aim(s): To assess survival in patient referred or not to an NSC.
Materials and methods: All patients with midgut NETs in Northern Ireland, current between 2000 and 2012 were identified. Those referred to the NSC and those managed in other hospitals were noted. The NI Cancer Registry, the NSC and the NET specialist Lab were used to identify patients. Patients were followed to 31/9/2013 or to death. Patients confirmed by pathology or biomarkers, syndrome and/or somatostatin scintigraphy +ve were included. Patients were also age matched at diagnosis to closest age match, (limits +/-6M) to remove age bias in the clinic group.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy E Ardill
Keywords: NET Clinics

To read results and conclusion, please login ...

Further abstracts you may be interested in

#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#876 Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)
Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Professor Joy E Ardill
Keywords: MGC
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2811 Improving Diagnosis Times as Part of the Transformation of the South Wales NET Service
Introduction: Transformation of the South Wales NET service in late 2017 introduced new specialised staff, gastroenterology-led clinics and improved MDTs with a particular emphasis on educating referring specialties. This has led to improved overall patient experience, satisfaction and quality of life. NETs are recognised world-wide for their lengthy diagnosis times.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kapish Amin